See more : Rimini Street, Inc. (RMNI) Income Statement Analysis – Financial Results
Complete financial analysis of Indivior PLC (INDV.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indivior PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- CannBioRx Life Sciences Corp. (ATNFW) Income Statement Analysis – Financial Results
- Zuleika Gold Limited (ZAG.AX) Income Statement Analysis – Financial Results
- Larsen & Toubro Limited (LTOUF) Income Statement Analysis – Financial Results
- New Age Metals Inc. (NMTLF) Income Statement Analysis – Financial Results
- NanJing Research Institute of Surveying, Mapping & Geotechnical Investigation, Co.Ltd (300826.SZ) Income Statement Analysis – Financial Results
Indivior PLC (INDV.L)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indivior.com
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 901.00M | 791.00M | 647.00M | 785.00M | 1.01B | 1.09B | 1.06B | 1.01B | 1.12B | 1.22B | 1.34B | 1.25B |
| Cost of Revenue | 186.00M | 159.00M | 127.00M | 97.00M | 140.00M | 128.00M | 104.00M | 107.00M | 97.00M | 95.00M | 104.00M | 94.00M | 81.00M |
| Gross Profit | 907.00M | 742.00M | 664.00M | 550.00M | 645.00M | 877.00M | 989.00M | 951.00M | 917.00M | 1.02B | 1.11B | 1.25B | 1.17B |
| Gross Profit Ratio | 82.98% | 82.35% | 83.94% | 85.01% | 82.17% | 87.26% | 90.48% | 89.89% | 90.43% | 91.48% | 91.45% | 92.98% | 93.54% |
| Research & Development | 106.00M | 72.00M | 52.00M | 40.00M | 53.00M | 91.00M | 89.00M | 119.00M | 148.00M | 115.00M | 76.00M | 41.00M | 35.00M |
| General & Administrative | 575.00M | 545.00M | 226.00M | 447.00M | 196.00M | 271.00M | 525.00M | 520.00M | 227.00M | 343.00M | 341.00M | 320.00M | 266.00M |
| Selling & Marketing | 236.00M | 218.00M | 192.00M | 202.00M | 199.00M | 205.00M | 163.00M | 144.00M | 166.00M | 147.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 811.00M | 763.00M | 418.00M | 649.00M | 395.00M | 476.00M | 688.00M | 664.00M | 393.00M | 343.00M | 341.00M | 320.00M | 266.00M |
| Other Expenses | -6.00M | -2.00M | 13.00M | 17.00M | 19.00M | 18.00M | 19.00M | 19.00M | 30.00M | 29.00M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 911.00M | 833.00M | 483.00M | 706.00M | 467.00M | 585.00M | 796.00M | 802.00M | 571.00M | 458.00M | 417.00M | 361.00M | 301.00M |
| Cost & Expenses | 1.10B | 992.00M | 610.00M | 803.00M | 607.00M | 713.00M | 900.00M | 909.00M | 668.00M | 553.00M | 521.00M | 455.00M | 382.00M |
| Interest Income | 43.00M | 19.00M | 4.00M | 9.00M | 24.00M | 17.00M | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 37.00M | 29.00M | 27.00M | 26.00M | 22.00M | 31.00M | 37.00M | 51.00M | 61.00M | 1.00M | 44.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 28.00M | 21.00M | 22.00M | 26.00M | 28.00M | 40.00M | 13.00M | 14.00M | 40.00M | 26.00M | 28.00M | 27.00M | 25.00M |
| EBITDA | 66.00M | -45.00M | 238.00M | -123.00M | 214.00M | 322.00M | 199.00M | 156.00M | 409.00M | 588.00M | 723.00M | 911.00M | 897.00M |
| EBITDA Ratio | 6.04% | -5.66% | 26.17% | -18.70% | 29.30% | 34.73% | 18.85% | 15.41% | 38.07% | 52.74% | 59.46% | 68.04% | 71.53% |
| Operating Income | -4.00M | -91.00M | 213.00M | -156.00M | 178.00M | 292.00M | 193.00M | 149.00M | 346.00M | 562.00M | 695.00M | 884.00M | 872.00M |
| Operating Income Ratio | -0.37% | -10.10% | 26.93% | -24.11% | 22.68% | 29.05% | 17.66% | 14.08% | 34.12% | 50.40% | 57.15% | 66.02% | 69.54% |
| Total Other Income/Expenses | 5.00M | -10.00M | -23.00M | -17.00M | 2.00M | -14.00M | -56.00M | -51.00M | -61.00M | -1.00M | -44.00M | 0.00 | 0.00 |
| Income Before Tax | 1.00M | -95.00M | 190.00M | -173.00M | 180.00M | 278.00M | 137.00M | 98.00M | 285.00M | 561.00M | 651.00M | 884.00M | 872.00M |
| Income Before Tax Ratio | 0.09% | -10.54% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% | 28.11% | 50.31% | 53.54% | 66.02% | 69.54% |
| Income Tax Expense | -1.00M | -42.00M | -15.00M | -25.00M | 46.00M | 3.00M | 79.00M | 63.00M | 57.00M | 158.00M | 193.00M | 277.00M | 258.00M |
| Net Income | 2.00M | -53.00M | 205.00M | -148.00M | 134.00M | 275.00M | 58.00M | 35.00M | 228.00M | 403.00M | 458.00M | 607.00M | 614.00M |
| Net Income Ratio | 0.18% | -5.88% | 25.92% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% | 22.49% | 36.14% | 37.66% | 45.33% | 48.96% |
| EPS | 0.01 | -0.38 | 1.41 | -1.01 | 0.92 | 1.89 | 0.40 | 0.25 | 1.60 | 2.80 | 3.40 | 4.12 | 4.17 |
| EPS Diluted | 0.01 | -0.36 | 1.35 | -0.96 | 0.89 | 1.83 | 0.40 | 0.25 | 1.55 | 2.80 | 3.40 | 4.12 | 4.17 |
| Weighted Avg Shares Out | 200.00M | 139.01M | 145.66M | 146.57M | 145.43M | 145.43M | 144.23M | 143.97M | 143.72M | 143.72M | 143.72M | 147.31M | 147.31M |
| Weighted Avg Shares Out (Dil) | 141.80M | 145.43M | 151.94M | 154.00M | 150.23M | 150.23M | 149.70M | 148.64M | 146.62M | 144.78M | 143.72M | 147.31M | 147.31M |
Source: https://incomestatements.info
Category: Stock Reports